Medical high-value consumables company inventory | Two-vote system to promote industry development

Medical Network July 17th In recent years, the use of implanted, invasive medical high-value consumables has been increasing year by year. Due to strict safety requirements and high added value, the consumables have higher unit prices.

For a long time, most of the sales models of medical consumables in China have been followed. drug Similarly, using the agent sales model, the products from the production enterprises to the medical institutions through the layer of agents, which there are layers of price increases and 'calls', 'trafficking' and other violations of the rules, resulting in the final use of the patient when the price and the factory The price difference is huge.

In order to reduce the price moisture caused by the intermediate links, most provinces and cities across the country have introduced policies to implement the 'two-vote system' for consumables, that is, to open a ticket from the production enterprise to the circulation enterprise, and the circulation enterprise to the medical institution to open another ticket. For example, 2017 In November, Anhui Food and Drug Administration, Health Planning Commission, Public Security Department, Industrial and Commercial Bureau, and the State Administration of Taxation jointly issued the "Two-vote System for the Implementation of Medical Supplies Purchase in Public Medical Institutions in Anhui Province" (Trial Implementation), to save medicine Purchasing platform public medical institutions medical consumables online centralized procurement catalogues, combined with the relevant requirements of the medical device catalogue, identified vascular interventions, non-vascular interventions, orthopedic implants, neurosurgery, electrophysiology, pacemakers, Extracorporeal circulation and blood purification, ophthalmology materials, stomatology, and other ten categories of high-value medical consumables implement the 'two-vote system'.

In the short term, the implementation of the two-vote system will lead producers to face channel model transformation and re-select proxy Business, product price adjustment and many other issues, but in the long run, the two-vote system will suppress the false high prices, which will in turn stimulate the growth of demand for medical high-value consumable products, and bring more benefits to the production enterprises. Promote the development of the industry.

Strictly speaking, medical high-value consumables are a wide range of concepts, including not only vascular and non-vascular interventions, orthopedic implants, but also electrophysiological, extracorporeal circulation and blood purification, ophthalmology and many other categories. .

Minimally invasive interventional therapy for vascular disease is one of the most representative techniques in the development of interventional therapy. The related interventional device industry has also developed rapidly. The stent has been developed to the fourth generation of degradable stents, and the balloon has also been eluted. Balloons and degradable balloons have emerged, and several types of absorbable occluders have been introduced abroad and entered the clinical stage.

Domestically listed vascular interventional devices are listed or listed on the New Third Board by Weigao Group, Lepu Medical, MicroPort Medical, Xianjian Technology, Kelly, Yiyi Bio, US-China Shuanghe, Electrophysiology, etc. These listed companies are related to blood vessels. The research and development strength of the stent is strong, and the vascular stent is the high-end of China. medical instruments The rare ones have basically realized the domestically replaced products.

Source: China Medical Device Industry Development Report (2017)

Among these companies, Xianjian Technology, Yiyi Bio, US-China Shuanghe and Electrophysiology are companies specializing in cardiovascular interventions, Xianjian Technology's occluder, electrophysiological 3D mapping system and RF. Ablation catheters are leading the country and the world.

Minimally Invasive Medicine, Weigao Group, Kelly and others have layouts in both cardiovascular intervention and orthopedic implants. Minimally invasive medical orthopedic implants cover almost all types of joints, trauma and spine, the Weigao Group The product line is more extensive, in addition to high-value consumables for interventional and implantable types, as well as hemodialysis consumables, as well as consumables and equipment for safe infusion, inspection and diagnosis, disinfection and many other fields.

In terms of innovative products, Xianjian Technology and MicroPort Medical have a number of products that have been included in the special approval list for innovative medical devices. Among them, Xianjian Technology has approved an occluder product and a pacemaker product, including minimally invasive medical treatment. A total of three products of its electrophysiology were approved.

Orthopedic implants can be divided into trauma, spine, joints and others. The market share of the first three can account for more than 80% of orthopedic devices. In addition, orthopedic implants include some for filling or repairing bone. Defective filling materials, mainly bone cement, bioceramics, hydroxyapatite, bioglass, allograft, allogeneic bone, etc.

In the global market, since the 1960s and 1970s, the five companies, Johnson & Johnson DePuy Synthes, Smith & Nephew, Medtronic, Stryker Stryker, and Zimmer Biomet, have gradually occupied global orthopedics through continuous investment and mergers and acquisitions. The leading position of high-value consumables, forming the pattern of the top five consumable supplies.

Representative listing in the field of orthopedic implants in China enterprise In addition to the above-mentioned Weigao and minimally invasive medicine, there are Chunli Medical, Dabo Medical, Aikang Medical, Kelly, Chuangsheng Holdings and Kanghui Medical.

Among them, Kanghui Medical, which was listed on the US stock market, was acquired by Medtronic in November 2012 as the first Medtronic business unit headquartered outside the US; Chuangsheng Holdings was one of the largest orthopedic equipment manufacturers in the world in January 2013. Secker acquired.

Ikang Medical, which went public in Hong Kong at the end of 2017, is the first and only medical device company in the Mainland to commercialize 3D printing technology and apply it to bone and joint and spinal replacement implants based on metal 3D printing technology. The 3D ACT artificial hip joint system was approved by the CFDA and became the first 3D printed orthopedic implant product in the country.

In the field of vascular intervention and orthopedic implants, which account for a large proportion in the field of medical high-value consumables, although many innovative companies and products have emerged in recent years, representative companies are still mostly A listed company with strong strength and high degree of commercialization.

However, in other fields, the performance of innovative companies is also very bright, such as the main participant in the heart valve field, Ming Medical, Suzhou Concentric in the artificial heart field, Suzhou Jia Lisheng in the field of drug-loaded microspheres, non-vascular intervention field. Changzhou Jiasen, IBONODE in the field of intraocular lenses.

From the market situation, in the medical high-value consumables market, foreign manufacturers represented by Johnson & Johnson and Medtronic are highly competitive in the middle and high-end products. Domestic manufacturers are constantly improving their innovation in the process of promoting localization in the country. Increasingly, the market share has gradually increased. Overall, the medical high-value consumables industry is affected by the integration of distribution channels under the implementation of the 'two-vote system'. The industry situation remains to be seen, but the incidence of diseases has not only increased, medical care Many factors, such as increasing demand, are still driving its rapid development.